{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:47:51Z","timestamp":1791920871124,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1016\/j.antiviral.2006.05.020","type":"journal-article","created":{"date-parts":[[2006,6,20]],"date-time":"2006-06-20T11:26:11Z","timestamp":1150802771000},"page":"254-259","source":"Crossref","is-referenced-by-count":62,"title":["Perspectives on the development of acyclic nucleotide analogs as antiviral drugs"],"prefix":"10.1016","volume":"71","author":[{"given":"William A.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2006.05.020_bib1","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1073\/pnas.88.4.1499","article-title":"Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound","volume":"88","author":"Balzarini","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2006.05.020_bib2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/AAC.37.2.332","article-title":"Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2, 6-diaminopurine","volume":"37","author":"Balzarini","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2006.05.020_bib3","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1128\/AAC.45.10.2733-2739.2001","article-title":"Phase I\/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-1 infected adults","volume":"45","author":"Barditch-Crovo","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2006.05.020_bib4","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1073\/pnas.80.9.2767","article-title":"Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1","volume":"80","author":"Cheng","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2006.05.020_bib5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/095632029500600403","article-title":"Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl)adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases \u03b1, b, and g","volume":"6","author":"Cherrington","year":"1995","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2006.05.020_bib6","doi-asserted-by":"crossref","unstructured":"Cihlar T., Ray A., Boojamra, D., et al., 2006. GS9148: A novel nucleotide active against HIV-1 variance with drug-resistance mutations in reverse transcriptase. 13th Conference on Retroviruses and Opportunistic Infections, February 5\u20138, 2006, Denver, CO.","DOI":"10.1097\/01.COH.0000239849.20828.09"},{"key":"10.1016\/j.antiviral.2006.05.020_bib7","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1128\/AAC.39.11.2401","article-title":"Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients","volume":"39","author":"Cundy","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2006.05.020_bib8","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1023\/A:1018925723889","article-title":"Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys","volume":"11","author":"Cundy","year":"1994","journal-title":"Pharm. Res."},{"key":"10.1016\/j.antiviral.2006.05.020_bib9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1128\/AAC.38.2.365","article-title":"Oral, subcutaneous, and intramuscular bioavailabilities of the antiviral nucleotide analog 9-(2-phosphonylmethoxyethyl)adenine in cynomolgus monkeys","volume":"38","author":"Cundy","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2006.05.020_bib10","unstructured":"Cundy, K.C., Shaw, J.P., 1995. Analysis of tissues from TSI Mason Sudy 2-R23. An open balance study of intravenous 14C-GS-0393 and oral 14C-GS-0840 administered to cynomolgus monkeys. Gilead Sciences Internal Report No. 93-DDM-0840-003."},{"key":"10.1016\/j.antiviral.2006.05.020_bib11","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1021\/js970264s","article-title":"Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs","volume":"86","author":"Cundy","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.antiviral.2006.05.020_bib12","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic nucleoside phosphonates: a key class of antiviral drugs","volume":"4","author":"De Clercq","year":"2005","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.antiviral.2006.05.020_bib13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/323464a0","article-title":"A novel selective broad-spectrum anti-DNA virus agent","volume":"323","author":"De Clercq","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2006.05.020_bib14","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1128\/AAC.42.9.2380","article-title":"Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults","volume":"42","author":"Deeks","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2006.05.020_bib15","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2006.05.020_bib16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1681\/ASN.V113383","article-title":"Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1","volume":"11","author":"Ho","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.antiviral.2006.05.020_bib17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/00365519209088371","article-title":"Effects of pivalic acid-containing prodrugs on carnitine homeostasis and on response to fasting in children","volume":"52","author":"Holme","year":"1992","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.antiviral.2006.05.020_bib18","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0040-4039(00)90598-7","article-title":"Synthesis of 5\u2019-deoxyuridine 5\u2019-phosphonic acid","volume":"8","author":"Holy","year":"1967","journal-title":"Tetrahedron Letters"},{"key":"10.1016\/j.antiviral.2006.05.020_bib19","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1021\/ja01021a086","article-title":"The synthesis of 6\u2032-deoxyhomonucleoside-6\u2032-phosphonic acids","volume":"90","author":"Jones","year":"1968","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2006.05.020_bib20","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/S0968-0896(00)00183-8","article-title":"Synthesis of phosphonate derivatives of uridine, cytidine, and cytosine arabinoside","volume":"8","author":"Jung","year":"2000","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.antiviral.2006.05.020_bib21","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1021\/jm049029u","article-title":"Design, synthesis, and antiviral activity of adenosine 5\u2032-phosphonate analogues as chain terminators against hepatitis C virus","volume":"48","author":"Koh","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2006.05.020_bib22","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1128\/AAC.49.5.1898-1906.2005","volume":"49","author":"Lee","year":"2005","journal-title":"AAC"},{"key":"10.1016\/j.antiviral.2006.05.020_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0166-3542(97)00043-0","volume":"36","author":"Mulato","year":"1997","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2006.05.020_bib24","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2006.05.020_bib25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1021\/jm00155a015","article-title":"Synthesis and antiherpes virus activity of phosphate and phosphonate derivatives of 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine","volume":"29","author":"Prisbe","year":"1986","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2006.05.020_bib26","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1128\/AAC.39.10.2304","article-title":"Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells","volume":"39","author":"Robbins","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2006.05.020_bib27","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/AAC.42.3.612","article-title":"Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl) PMPA","volume":"42","author":"Robbins","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2006.05.020_bib28","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1023\/A:1018907431893","article-title":"Biological screens of PMEA prodrugs","volume":"10","author":"Shaw","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.antiviral.2006.05.020_bib29","first-page":"362","article-title":"Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats","volume":"25","author":"Shaw","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.antiviral.2006.05.020_bib30","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1023\/A:1012108719462","article-title":"Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs","volume":"14","author":"Shaw","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.antiviral.2006.05.020_bib31","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1128\/AAC.37.10.2247","volume":"37","author":"Srinivas","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2006.05.020_bib32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0166-3542(92)90084-I","article-title":"Synthesis and in vitro evaluation of a phosphate prodrug: bis(pivaloyloxymethyl)9-(2-phosphonylmethoxyethyl)adenine","volume":"19","author":"Starrett","year":"1992","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2006.05.020_bib33","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1021\/jm00038a015","article-title":"Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA)","volume":"37","author":"Starrett","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2006.05.020_bib34","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1126\/science.270.5239.1197","article-title":"Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine","volume":"270","author":"Tsai","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2006.05.020_bib35","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1128\/JVI.73.4.2947-2955.1999","article-title":"Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques","volume":"73","author":"Van Rompay","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2006.05.020_bib36","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1021\/bi00875a036","article-title":"Nucleoside phosphonic acids. I. The synthesis of 5\u2032-deoxyuridine 5\u2032-phosphonic acids and derivatives","volume":"5","author":"Yengoyan","year":"1966","journal-title":"Biochemistry"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354206001719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354206001719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T15:08:08Z","timestamp":1627484888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354206001719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":36,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S0166354206001719"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2006.05.020","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}